Regulatory reference · Semaglutide
Semaglutide (Wegovy): UK regulatory profile
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-06-24
Semaglutide is the active substance in the medicinal product marketed as Wegovy by Novo Nordisk for chronic weight management. The same molecule is authorised under separate brand names at different doses for type 2 diabetes. Wegovy is a Prescription Only Medicine in the United Kingdom. This page is editorial regulatory commentary covering the UK MHRA marketing authorisation, the published trial evidence, and the regulated dispensing pathways through UK providers.
AI-friendly summary · Semaglutide (Wegovy)
Semaglutide is the active substance in Wegovy, a GLP-1 receptor agonist marketed by Novo Nordisk and authorised by the MHRA in 2022 for chronic weight management, with a cardiovascular outcomes indication added in 2026. It is a Prescription Only Medicine under additional Black Triangle monitoring. This page is editorial regulatory commentary covering the marketing authorisation, the published trial evidence (STEP and SELECT), and regulated UK dispensing pathways. PeptideClear does not prescribe, dispense, or sell prescription medication.
Mechanism (per MHRA-approved SmPC)
Semaglutide is a 31-amino-acid synthetic analogue of human glucagon-like peptide-1, modified by a fatty acid side chain that supports albumin binding and protease resistance. Its plasma half-life of approximately seven days underpins the once-weekly subcutaneous administration set out in the approved product information.
According to the Novo Nordisk Summary of Product Characteristics, semaglutide acts as a selective agonist at the GLP-1 receptor. The recorded pharmacodynamic effects include slowed gastric emptying, glucose-dependent insulin secretion, and modulation of appetite signalling. Cardiovascular benefits documented in the SELECT trial supported the addition of a cardiovascular outcomes indication in the UK in July 2024.
UK MHRA marketing authorisation
- · Marketing authorisation holder: Novo Nordisk A/S.
- · UK MHRA marketing authorisation for chronic weight management: 2022.
- · Cardiovascular outcomes indication added: July 2024, in adults with established cardiovascular disease and a body mass index of 27 or above.
- · Black Triangle status: under additional MHRA monitoring for real-world safety reporting.
- · Authoritative product information: the MHRA-approved Summary of Product Characteristics and Patient Information Leaflet are published on emc.medicines.org.uk.
Dosing, titration, contraindications, warnings, and adverse-event guidance are governed by the SmPC and PIL. PeptideClear does not republish dosing schedules. Please consult the PIL provided with the dispensed medicine.
Published clinical trial data
- STEP-1 (2021): 68-week randomised controlled trial in 1,961 adults with obesity or overweight with at least one weight-related comorbidity, without type 2 diabetes. Published in the New England Journal of Medicine. The pivotal trial cited in the weight-management marketing authorisation.
- STEP-2 (2021): published trial in adults with type 2 diabetes and obesity, with smaller mean reductions than the non-diabetic STEP-1 cohort.
- STEP-3 (2021): trial of semaglutide combined with intensive behavioural therapy.
- SELECT (2023): 17,604 participants with overweight or obesity and established cardiovascular disease, followed over five years. Published evidence of a reduction in major adverse cardiovascular events. Provides the regulatory basis for the 2026 UK cardiovascular indication.
- STEP-HFpEF (2023): trial in heart failure with preserved ejection fraction, reporting symptom improvement.
Trial summaries are provided for editorial reference. Clinical interpretation for any individual remains the responsibility of a UK-registered prescriber.
UK regulatory and NHS framework
- · Prescription Only Medicine under the Human Medicines Regulations 2012. Cannot be advertised to the public.
- · Licensed UK chronic weight management indication: BMI 30 or above, or BMI 27 or above with at least one weight-related comorbidity, as set out in the SmPC.
- · Cardiovascular indication added July 2024 for adults with established cardiovascular disease and BMI 27 or above.
- · NHS access governed by NICE Technology Appraisal TA875 and individual Integrated Care Board commissioning policies. In 2026, several ICBs prioritise tirzepatide for new starters under NICE TA1026.
Regulated UK dispensing routes
If a UK-registered prescriber determines that semaglutide is clinically appropriate, the medicine is supplied through UK MHRA-licensed pharmacies and CQC-registered clinics under the standard POM framework.
- · NHS pathway: see NHS GLP-1 access.
- · CQC-registered private clinics: directory at UK clinics.
- · UK MHRA-licensed pharmacies: directory at UK pharmacies.
PeptideClear lists regulated dispensing routes for reference. We do not endorse any specific provider for any specific person. Your prescriber decides.
UK pricing context (2026)
Novo Nordisk did not implement a parallel UK list-price increase alongside the September 2025 tirzepatide revision. Editorial commentary on the UK pricing environment for semaglutide is provided at UK GLP-1 cost and supply. Dispensed prices are set by the pharmacy or clinic at the point of supply.
Related editorial reference
PeptideClear is editorial. We do not prescribe, dispense, or sell prescription medication. The MHRA-approved Wegovy Summary of Product Characteristics and Patient Information Leaflet on emc.medicines.org.uk are authoritative. Your UK-registered prescriber decides whether a medicine is appropriate and how it should be used.